{"id":2338,"date":"2021-04-15T12:56:10","date_gmt":"2021-04-15T12:56:10","guid":{"rendered":"http:\/\/www.peptonicmedical.se\/?p=2338"},"modified":"2022-08-17T20:56:19","modified_gmt":"2022-08-17T20:56:19","slug":"arsredovisning-for-peptonic-medical-ab-publ-for-verksamhetsaret-2020-ar-publicerad","status":"publish","type":"post","link":"https:\/\/www.peptonicmedical.se\/en\/arsredovisning-for-peptonic-medical-ab-publ-for-verksamhetsaret-2020-ar-publicerad\/","title":{"rendered":"\u00c5rsredovisning f\u00f6r Peptonic Medical AB (publ) f\u00f6r verksamhets\u00e5ret 2020 \u00e4r publicerad"},"content":{"rendered":"\n<p>Er tryckt kopia av \u00e5rsredovisningen kan best\u00e4llas via e-post&nbsp;<a href=\"mailto:info@peptonicmedical.se\">info@peptonicmedical.se<\/a>&nbsp;eller via telefon <span style=\"white-space: nowrap;\">0768-550 200<\/span><\/p>\n\n\n\n<p>Du kan ladda ner \u00e5rsredovisningen som PDF h\u00e4r:<\/p>\n\n\n\n<p class=\"button color\"><a style=\"color: #FFFFFF;\" href=\"https:\/\/www.peptonicmedical.se\/wp-content\/uploads\/2021\/04\/Peptonic-Medical_Annual-report-2020_Signed.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Ladda ner \u00e5rsredovisningen f\u00f6r 2020<\/a><\/p>\n\n\n\n<p><br><strong>Kontakt<\/strong><br>Erik Sundquist,&nbsp;VD&nbsp;<br>Telefon: + 46 722 49 90 43<br>E-post:&nbsp;<a href=\"mailto:erik.sundquist@peptonicmedical.se\">erik.sundquist@peptonicmedical.se<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity is-style-wide\"\/>\n\n\n\n<h3>Om Peptonic Medical AB<\/h3>\n\n\n\n<p>Peptonic Medical AB (publ) \u00e4r ett innovativt biomedicinskt f\u00f6retag som bedriver forskning kring och utveckling av l\u00e4kemedel och medicintekniska produkter inom omr\u00e5det kvinnoh\u00e4lsa. V\u00e5r vision \u00e4r att erbjuda s\u00e4kra och effektiva behandlingar f\u00f6r kvinnospecifika sjukdomar och medicinska tillst\u00e5nd. Peptonic Medical lanserade VagiVital\u00ae i juli 2018. Detta \u00e4r en hormonfri produkt f\u00f6r behandling av vaginal atrofi och vaginal torrhet. I bolagets utvecklingsprogram finns \u00e4ven Vagitocin\u00ae &#8211; en produkt som inneh\u00e5ller oxytocin f\u00f6r behandling av vaginal atrofi. Utvecklingen av Vagitocin\u00ae har lagts p\u00e5 is i v\u00e4ntan p\u00e5 ny information avseende oxytocinets verkningsmekanism i denna indikation. Bolaget grundades 2009 och aktien handlas sedan 2014 p\u00e5 Spotlight (<a href=\"https:\/\/www.spotlightstockmarket.com\" target=\"_blank\" rel=\"noreferrer noopener\">www.spotlightstockmarket.com<\/a>, &nbsp;kortkod: PMED) i Stockholm.<\/p>\n\n\n\n<p>Sedan augusti 2020 ing\u00e5r Lune Group Oy Ltd. som ett hel\u00e4gt dotterbolag i Peptonic Medical -koncernen.&nbsp; Lune Group Oy Ltd. \u00e4r ett f\u00f6retag grundat av Heli Kurjanen \u00e5r 2005. F\u00f6retagets aff\u00e4rsid\u00e9 \u00e4r att leda en l\u00e4ttsam mensrevolution i en positiv anda. Bolaget har genom att fokusera p\u00e5 h\u00e5llbar utveckling, milj\u00f6fr\u00e5gor och fr\u00e4mjande av sexualh\u00e4lsa utvecklats till att g\u00e5 i t\u00e4ten f\u00f6r menskoppsf\u00f6retagen. Lunette\u00ae&nbsp;menskoppar \u00e4r ett alternativ till eng\u00e5ngsmensskydd och h\u00e5ller i flera \u00e5r. F\u00f6retaget har \u00e5terf\u00f6rs\u00e4ljare i 50 l\u00e4nder och s\u00e4ljer via sin webbshop Lunette-produkter till \u00f6ver 100 l\u00e4nder. Lune Group har i USA dotterbolaget Lune North America Inc. Lunette\u00ae&nbsp;menskoppar \u00e4r designade, tillverkade och f\u00f6rpackade i Finland. Mer information om Lunette\u00ae&nbsp;f\u00e5r du genom att bes\u00f6ka<a href=\"https:\/\/file\/\/\/Users\/johaninborr\/Dropbox%20(PEPTONIC)\/Dropbox%20for%20Business%20reports\/Pressmeddelanden%202020\/%C2%A0https:\/se.lunette.com\">&nbsp;https:\/\/<\/a><a href=\"https:\/\/file\/\/\/Users\/johaninborr\/Dropbox%20(PEPTONIC)\/Dropbox%20for%20Business%20reports\/Pressmeddelanden%202020\/%C2%A0https:\/se.lunette.com\" target=\"_blank\" rel=\"noreferrer noopener\">se.lunette.com<\/a><a href=\"https:\/\/file\/\/\/Users\/johaninborr\/Dropbox%20(PEPTONIC)\/Dropbox%20for%20Business%20reports\/Pressmeddelanden%202020\/%C2%A0https:\/se.lunette.com\">\/<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Er tryckt kopia av \u00e5rsredovisningen kan best\u00e4llas via e-post&nbsp;info@peptonicmedical.se&nbsp;eller via telefon 0768-550 200 Du kan ladda ner \u00e5rsredovisningen som PDF h\u00e4r: Ladda ner \u00e5rsredovisningen f\u00f6r 2020 KontaktErik Sundquist,&nbsp;VD&nbsp;Telefon: + 46 722 49 90 43E-post:&nbsp;erik.sundquist@peptonicmedical.se Om Peptonic Medical AB Peptonic Medical AB (publ) \u00e4r ett innovativt biomedicinskt f\u00f6retag som bedriver forskning kring och utveckling av l\u00e4kemedel [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[3,20],"tags":[],"_links":{"self":[{"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/posts\/2338"}],"collection":[{"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/comments?post=2338"}],"version-history":[{"count":5,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/posts\/2338\/revisions"}],"predecessor-version":[{"id":3927,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/posts\/2338\/revisions\/3927"}],"wp:attachment":[{"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/media?parent=2338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/categories?post=2338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/tags?post=2338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}